Every material Form 8-K Sagimet Biosciences Inc. has filed with the SEC since September 30, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Sagimet Biosciences filed an updated investor presentation on October 22, 2026, furnished under Regulation FD rather than filed. The deck reports that the first patient was dosed in the AURORA Phase 3 acne trial in the US in October 2026, and it cites $257.6 million in cash as of June 30, 2026, which the company expects to fund operations through mid-2029.
Updated investor presentation dated October 22, 2026, attached as Exhibit 99.1 and furnished under Item 7.01
First patient dosed in the AURORA Phase 3 acne trial in the US in October 2026; topline results expected in 2H 2027
$257.6 million cash, cash equivalents and marketable securities as of June 30, 2026 (unaudited), plus a $115 million underwritten offering completed in September 2026
Sagimet Biosciences agreed on September 30, 2026 to sell 8,750,010 shares of Series A common stock at $10.00 per share and pre-funded warrants for up to 2,750,010 shares, with net proceeds expected to be $107.5 million. The company plans to use the proceeds with its existing cash to fund a Phase 3 trial of denifanstat in acne, pre-launch activities, and other clinical and corporate needs, and the offering is expected to close on October 1, 2026.
8,750,010 common shares offered at $10.00 per share, plus pre-funded warrants for up to 2,750,010 shares
Expected net proceeds of $107.5 million after underwriting discounts and commissions
Offering expected to close October 1, 2026, subject to customary closing conditions
Underwriters include Leerink Partners LLC, TD Securities (USA) LLC and Guggenheim Securities, LLC as representatives
Sagimet reported 52-week results from the open-label extension of a Phase 3 acne trial of denifanstat, run by license partner Ascletis in China, with results presented at EADV 2026. The company also terminated its at-the-market stock sale prospectus supplement, so it will not sell shares under the Leerink Partners sales agreement unless a new prospectus or registration statement is filed.
Extension trial reported 57% IGA success, 72% reduction in total lesions and 77% reduction in inflammatory lesions
Denifanstat was generally well-tolerated, with no adverse event-related permanent discontinuations
At-the-market prospectus supplement suspended and terminated effective September 30, 2026
Patient screening for the US AURORA Phase 3 trial is expected to begin in October 2026
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Sagimet Biosciences Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →